Kite, a Gilead Sciences company, will share four posters that add to the growing body of evidence to support the clinical use of its chimeric antigen receptor (CAR) T-cell therapy portfolio, at the ...

In a statement sent to Fierce Pharma Marketing, Cindy Perettie, executive VP and global head of Kite, welcomed Heath to his new role, adding, “Brian is an accomplished industry professional with ...

Gilead has completed its $11.9 billion landmark acquisition of Kite Pharma, as the pharma switches focus from hepatitis C to cancer and revolutionary CAR-T therapies. The California-based pharma ...

Through its partnership in 2017 with California-based Kite Pharma, Fosun Pharma has been ... Thanks to the nonstop global network it took only 48 hours to complete the plan for its development ...

The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an ...